id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15868 R65354 |
Dreier (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Intellectual disability - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
2.12 [1.32;3.39] C excluded (control group) |
36/2,665 34/5,288 | 70 | 2,665 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15869 R65370 |
Dreier (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Intellectual disability - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: Yes | 1.11 [0.73;1.70] | 36/2,665 184/22,203 | 220 | 2,665 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S386 R17415 |
Meador (Carbamazepine), 2013 | IQ <70 (DAS) (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 3.71 [0.15;92.65] C | 1/61 0/74 | 1 | 61 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6106 R15984 |
Titze (Carbamazepine) (Controls unexposed, disease free), 2008 | Learning disability (IQ<70) (German versions of the revised Wechsler Intelligence Scales for children and for adults) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
13.86 [0.24;809.27] C excluded (control group) |
0/4 0/49 | 0 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6112 R15987 |
Titze (Carbamazepine) (Controls unexposed, sick), 2008 | Learning disability (IQ<70) (German versions of the revised Wechsler Intelligence Scales for children and for adults) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.10 [0.04;33.38] C | 0/4 1/13 | 1 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5831 R14433 |
Viinikainen (Carbamazepine) b, 2006 | Full Scale IQ (FIQ) < 2SD Wechsler Intelligence Scale for Children (WISC III) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.00 [0.02;54.47] C | 0/13 0/13 | 0 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5560 R19152 |
Vinten (Carbamazepine), 2005 | IQ score <69 Wechsler Intelligence Scale for Children (WISC III) (Aged between 6 and 16 years) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 1.03 [0.28;3.83] C | 4/52 6/80 | 10 | 52 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7236 R20865 |
Gaily (Carbamazepine) (Controls unexposed, disease free), 2004 | Mental retardation (Verbal and nonverbal IQ <70) | 2nd and/or 3rd trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
0.54 [0.06;5.29] C excluded (control group) |
1/86 3/141 | 4 | 86 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5557 R20856 |
Gaily (Carbamazepine) (Controls unexposed, sick), 2004 | Mental retardation (Verbal and nonverbal IQ <70) | 2nd and/or 3rd trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.25 [0.02;2.87] C | 1/86 2/45 | 3 | 86 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 6 studies | 1.08 [0.73;1.59] | 235 | 2,881 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Epilepsy) (Controls unexposed, sick; 2: Carbamazepine; 3: Carbamazepine) (Controls unexposed, sick; 4: Carbamazepine) ; 5: Carbamazepine; 6: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.7640 (by Egger's regression)
slope=0.1191 (0.1919); intercept=-0.1267 (0.3941); t=0.3214; p=0.7640
excluded 7236, 6106, 15868